why choose us

First received: November 09, 2022

Clinical Trial: AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Advanced Pancreatic Ductal Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of AGEN1423, an Anti-CD73-TGF?-Trap Bifunctional Antibody, in Combination With Balstilimab, With or Without Chemotherapy in Subjects With Advanced Pancreatic Cancer.

Brief Summary: The goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Balstilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least one previous line of cancer therapy.The names of the study drugs involved in this study are:AGEN1423BalstilimabParticipants will receive study treatment for about 2 years and will be followed for 1 year after.

Read more